Emerging role of cannabinoids in gastrointestinal and liver diseases: Basic and clinical aspects

Gut

Volumn 57, Issue 8, 2008, Pages 1140-1155

  Izzo, A A ^a   Camilleri, M ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b Clinical Enteric Neuroscience Translational and Epidemiological Research Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLYL ISOTHIOCYANATE; ANANDAMIDE; ANTINEOPLASTIC AGENT; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID 2 RECEPTOR; CANNABIS; DEXTRAN SULFATE; DINITROBENZENESULFONIC ACID; DRONABINOL; ENDOCANNABINOID; METOCLOPRAMIDE; NABILONE; NITROBENZENE DERIVATIVE; PROCHLORPERAZINE; RIMONABANT; SEROTONIN 3 ANTAGONIST;

AGGRESSION; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ANXIETY; BEDTIME DOSAGE; BILE DUCT CARCINOMA; BILE DUCT DISEASE; CELL GROWTH; CELL REGENERATION; CHOLERA; CHOLESTASIS; CHOLESTATIC PRURITUS; DEPRESSION; DIZZINESS; DROWSINESS; DRUG APPROVAL; DYSENTERY; DYSPHORIA; ENTERITIS; EPITHELIUM CELL; EUPHORIA; FATTY LIVER; FIBROGENESIS; FOOD INTAKE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL REFLUX; HALLUCINATION; HEPATIC ENCEPHALOPATHY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INTESTINE MOTILITY; INTESTINE SECRETION; IRRITABILITY; IRRITABLE COLON; LIVER CANCER; LIVER DISEASE; LIVER FIBROSIS; LIVER ISCHEMIA; MENTAL DISEASE; METABOLIC DISORDER; MOTOR PERFORMANCE; NAUSEA; NONHUMAN; OBESITY; PANCREAS CANCER; PANCREAS SECRETION; PARANOIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PRURITUS; REVIEW; SEDATION; SIDE EFFECT; SOMNOLENCE; STOMACH EMPTYING; VISCERAL PAIN; VOMITING;

ANIMALS; CANNABINOIDS; ENDOCANNABINOIDS; GASTROINTESTINAL DISEASES; GASTROINTESTINAL TRACT; HUMANS; LIGANDS; LIVER DISEASES; RECEPTORS, CANNABINOID;

EID: 48249136051     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2008.148791     Document Type: Review

References (197)

1. Duncan M, Davison JS, Sharkey KA. Endocannabinoids and their receptors in the enteric nervous system. Aliment Pharmacol Ther 2005;22:667-83.
2. Coutts AA, Izzo AA. The gastrointestinal pharmacology of cannabinoids. An update. Curr Opin Pharmacol 2004;4:572-9.
3. Izzo AA, Capasso F. Marijuana for cholera therapy. Trends Pharmacol Sci 2006;27:7-8.
4. Massa F, Storr M, Lutz B. The endocannabinoid system in the physiology and pathophysiology of the gastrointestinal tract. J Mol Med 2005;83:944-54.
5. Sanger GJ. Endocannabinoids and the gastrointestinal tract: what are the key questions? Br J Pharmacol 2007;152:663-70.
6. Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006, 58:389-462.
7. Van Sickle MD, Duncan M, Kingsley PJ, et al. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 2005;310:329-32.
8. Di Marzo V, Petrosino S. Endocannabinoids and the regulation of their levels in health and disease. Curr Opin Lipidol 2007;18:129-40.
9. Liu J, Wang L, Harvey-White J, et al. A biosynthetic pathway for anandamide. Proc Natl Acad Sci USA 2006;103:13345-50.
10. Matias I, Gonthier MP, Petrosino S, et al. Role and regulation of acylethanolamides in energy balance: focus on adipocytes and beta-cells. Br J Pharmacol 2007;152:676-90.
11. Kunos G, Pacher P. Cannabinoids cool the intestine. Nat Med 2004;10:678-9.
12. Starowicz K, Nigam S, Di Marzo V. Biochemistry and pharmacology of endovanilloids. Pharmacol Ther 2007;114:13-33.
13. Pertwee RG. GPR55: a new member of the cannabinoid receptor clan? Br J Pharmacol 2007;152:984-6.
14. Brown AJ. Novel cannabinoid receptors. Br J Pharmacol 2007;152:567-75.
15. Hornby PJ, Prouty SM. Involvement of cannabinoid receptors in gut motility and visceral perception. Br J Pharmacol 2004;141:1335-45.
16. Di Marzo V, Izzo AA. Endocannabinoid overactivity and intestinal inflammation. Gut 2006;55:1373-6.
17. Casu MA, Porcella A, Ruiu S, et al. Differential distribution of functional cannabinoid CB1 receptors in the mouse gastroenteric tract. Eur J Pharmacol 2003;459:97-105.
18. Derbenev AV, Stuart TC, Smith BN. Cannabinoids suppress synaptic input to neurones of the rat dorsal motor nucleus of the vagus nerve. J Physiol 2004;559:923-38.
19. Burdyga G, Varro A, Dimaline R, et al. Ghrelin receptors in rat and human nodose ganglia: putative role in regulating CB-1 and MCH receptor abundance. Am J Physiol Gastrointest Liver Physiol 2006;290: G1289-97.
20. Kulkarni-Narla A, Brown DR. Localization of CB1-cannabinoid receptor immunoreactivity in the porcine enteric nervous system. Cell Tissue Res 2000;302:73-80.
21. MacNaughton WK, Van Sickle MD, Keenan CM, et al. Distribution and function of the cannabinoid-1 receptor in the modulation of ion transport in the guinea pig ileum: relationship to capsaicin-sensitive nerves. Am J Physiol Gastrointest Liver Physiol 2004;286:G863-71.
22. Anavi-Goffer S, Coutts AA. Cellular distribution of vanilloid VR1 receptor immunoreactivity in the guinea-pig myenteric plexus. Eur J Pharmacol 2003;458:61-71.
23. Adami M, Frati P, Bertini S, et al. Gastric antisecretory role and immunohistochemical localization of cannabinoid receptors in the rat stomach. Br J Pharmacol 2002;135:1598-606.
24. Burdyga G, Lal S, Varro A, et al. Expression of cannabinoid CB1 receptors by vagal afferent neurons is inhibited by cholecystokinin. J Neurosci 2004;24:2708-15.
25. Mascolo N, Izzo AA, Ligresti A, et al. The endocannabinoid system and the molecular basis of paralytic ileus in mice. FASEB J 2002;16:1973-5.
26. Izzo AA, Capasso F, Costagliola A, et al. An endogenous cannabinoid tone attenuates cholera toxin-induced fluid accumulation in mice. Gastroenterology 2003;125:765-74.
27. Pinto L, Izzo AA, Cascio MG, et al. Endocannabinoids as physiological regulators of colonic propulsion in mice. Gastroenterology 2002;123:227-34.
28. Storr M, Sibaev A, Marsicano G, et al. Cannabinoid receptor type 1 modulates excitatory and inhibitory neurotransmission in mouse colon. Am J Physiol Gastrointest Liver Physiol 2004;286:G110-7.
29. Wright K, Rooney N, Feeney M, et al. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology 2005;129:437-53.
30. Hinds NM, Ullrich K, Smid SD. Cannabinoid 1 (CB1) receptors coupled to cholinergic motorneurones inhibit neurogenic circular muscle contractility in the human colon. Br J Pharmacol 2006;148:191-9.
31. Wright KL, Duncan M, Sharkey KA. Cannabinoid CB(2) receptors in the gastrointestinal tract: a regulatory system in states of inflammation. Br J Pharmacol 2008;153:263-70.
32. Izzo AA, Fezza F, Capasso R, et al. Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. Br J Pharmacol 2001;134:563-70.
33. Massa F, Marsicano G, Hermann H, et al. The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest 2004;113:1202-9.
34. Kimball ES, Schneider CR, Wallace NH, et al. Agonists of cannabinoid receptor 1 and 2 inhibit experimental colitis induced by oil of mustard and by dextran sulfate sodium. Am J Physiol Gastrointest Liver Physiol 2006;291:G364-71.
35. D'Argenio G, Valenti M, Scaglione G, et al. Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation. FASEB J 2006;20:568-70.
36. Ligresti A, Bisogno T, Matias I, et al. Possible endocannabinoid control of colorectal cancer growth. Gastroenterology 2003;125:677-87.
37. D'Argenio G, Petrosino S, Gianfrani C, et al. Overactivity of the intestinal endocannabinoid system in celiac disease and in methotrexate-treated rats. J Mol Med 2007;85:523-30.
38. Guagnini F, Valenti M, Mukenge S, et al. Neural contractions in colonic strips from patients with diverticulosis: role of endocannabinoids and substance P. Gut 2006;55:946-53.
39. Storr MA, Sharkey KA. The endocannabinoid system and gut-brain signalling. Curr Opin Pharmacol 2007;7:575-82.
40. McVey DC, Schmid PC, Schmid HH, et al. Endocannabinoids induce ileitis in rats via the capsaicin receptor (VR1). J Pharmacol Exp Ther 2003;304:713-22.
41. Izzo AA, Aviello G, Petrosino S, et al. Increased endocannabinoid levels reduce the development of precancerous lesions in the mouse colon. J Mol Med 2008;86:89-98.
42. Darmani NA, McClanahan BA, Trinh C, et al. Cisplatin increases brain 2-arachidonoylglycerol (2-AG) and concomitantly reduces intestinal 2-AG and anandamide levels in the least shrew. Neuropharmacology 2005;49:502-13.
43. Maccarrone M, Bari M, Battista N, et al. Estrogen stimulates arachidonoylethanolamide release from human endothelial cells and platelet activation. Blood 2002;100:4040-8.
44. Rossi C, Pini LA, Cupini ML, et al. Endocannabinoids in platelets of chronic migraine patients and medication-overuse headache patients: relation with serotonin levels. Eur J Clin Pharmacol 2008;64:1-8.
45. Maccarrone M, De Petrocellis L, Bari M, et al. Lipopolysaccharide downregulates fatty acid amide hydrolase expression and increases anandamide levels in human peripheral lymphocytes. Arch Biochem Biophys 2001;393:321-8.
46. Ahluwalia J, Yaqoob M, Urban L, et al. Activation of capsaicin-sensitive primary sensory neurones induces anandamide production and release. J Neurochem 2003;84:585-91.
47. Aviello G, Matias I, Capasso R, et al. Inhibitory effect of the anorexic compound oleoylethanolamide on gastric emptying in control and overweight mice. J Mol Med 2008;86:416-22.
48. Fu J, Astarita G, Gaetani S, et al. Food intake regulates oleoylethanolamide formation and degradation in the proximal small intestine. J Biol Chem 2007;282:1518-28.
49. Katayama K, Ueda N, Kurahashi Y, et al. Distribution of anandamide amidohydrolase in rat tissues with special reference to small intestine. Biochim Biophys Acta 1997;1347:212-8.
50. Capasso R, Matias I, Lutz B, et al. Fatty acid amide hydrolase controls mouse intestinal motility in vivo. Gastroenterology 2005;129:941-51.
51. Matias I, Di Marzo V. Endocannabinoids and the control of energy balance. Trends Endocrinol Metab 2007;18:27-37.
52. Kunos G. Understanding metabolic homeostasis and imbalance: what is the role of the endocannabinoid system? Am J Med 2007;120(9 Suppl 1):S18-24
53. Van Sickle MD, Oland LD, Ho W, et al. Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret. Gastroenterology 2001;121:767-74.
54. Parker LA, Kwiatkowska M, Mechoulam R. Delta-9- tetrahydrocannabinol and cannabidiol, but not ondansetron, interfere with conditioned retching reactions elicited by a lithium-paired context in Suncus murinus: an animal model of anticipatory nausea and vomiting. Physiol Behav 2006;87:66-71.
55. Darmani NA, Johnson JC. Central and peripheral mechanisms contribute to the antiemetic actions of delta-9-tetrahydrocannabinol against 5-hydroxytryptophan-induced emesis. Eur J Pharmacol 2004;488:201- 12.
56. Sharkey KA, Cristino L, Oland LD, et al. Arvanil, anandamide and N-arachidonoyl-dopamine (NADA) inhibit emesis through cannabinoid CB1 and vanilloid TRPV1 receptors in the ferret. Eur J Neurosci 2007;25:2773-82.
57. Coruzzi G, Adami M, Guaita E, et al. Effects of cannabinoid receptor agonists on rat gastric acid secretion: discrepancy between in vitro and in vivo data. Dig Dis Sci 2006;51:310-7.
58. Germano MP, D'Angelo V, Mondello MR, et al. Cannabinoid CB1-mediated inhibition of stress-induced gastric ulcers in rats. Naunyn Schmiedebergs Arch Pharmacol 2001;363:241-4.
59. Dembinski A, Warzecha Z, Ceranowicz P, et al. Cannabinoids in acute gastric damage and pancreatitis. J Physiol Pharmacol 2006;57:137-54.
60. Rutkowska M, Fereniec-Goltbiewska L. ACEA (arachidonyl-2- chloroethylamide), the selective cannabinoid CB1 receptor agonist, protects against aspirin-induced gastric ulceration. Pharmazie 2006;61:341-2.
61. Lehmann A, Blackshaw LA, Branden L, et al. Cannabinoid receptor agonism inhibits transient lower esophageal sphincter relaxations and reflux in dogs. Gastroenterology 2002;123:1129-34.
62. Partosoedarso ER, Abrahams TP, Scullion RT, et al. Cannabinoid1 receptor in the dorsal vagal complex modulates lower oesophageal sphincter relaxation in ferrets. J Physiol 2003;550:149-58.
63. Izzo AA, Mascolo N, Capasso R, et al. Inhibitory effect of cannabinoid agonists on gastric emptying in the rat. Naunyn Schmiedebergs Ach Pharmacol 1999;360:221-3.
64. Krowicki ZK, Moerschbaecher JM, Winsauer PJ, et al. Delta9-tetrahydrocannabinol inhibits gastric motility in the rat through cannabinoid CB1 receptors. Eur J Pharmacol 1999;371:187-96.
65. Carai MA, Colombo G, Gessa GL, et al. Investigation on the relationship between cannabinoid CB1 and opioid receptors in gastrointestinal motility in mice. Br J Pharmacol 2006;148:1043-50.
66. Sanson M, Bueno L, Fioramonti J. Involvement of cannabinoid receptors in inflammatory hypersensitivity to colonic distension in rats. Neurogastroenterol Motil 2006;18:949-56.
67. Izzo AA. The cannabinoid CB(2) receptor: a good friend in the gut. Neurogastroenterol Motil 2007;19:704-8.
68. Darmani NA. Delta(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB(1) receptor antagonist/inverse agonist SR 141716A. Neuropsychopharmacology 2001;24:198-203.
69. Di Marzo V, Capasso R, Matias I, et al. The role of endocannabinois in the regulation of gastric emptying: alterations in mice fed a high-fat diet. Br J Pharmacol 2008;153:1272-80.
70. Ward SM, Bayguinov J, Won KJ, et al. Distribution of the vanilloid receptor (VR1) in the gastrointestinal tract. J Comp Neurol 2003;465:121-35.
71. Holzer P. TRPV1 and the gut: from a tasty receptor for a painful vanilloid to a key player in hyperalgesia. Eur J Pharmacol 2004;500:231-41.
72. Mang CF, Erbelding D, Kilbinger H. Differential effects of anandamide on acetylcholine release in the guinea-pig ileum mediated via vanilloid and non-CB1 cannabinoid receptors. Br J Pharmacol 2001;134:161-7.
73. Smid SD, Bjorklund CK, Svensson KM, et al. The endocannabinoids anandamide and 2-arachidonoylglycerol inhibit cholinergic contractility in the human colon. Eur J Pharmacol 2007;575:168-76.
74. Salamone JD, McLaughlin PJ, Sink K, et al. Cannabinoid CB1 receptor inverse agonists and neutral antagonists: effects on food intake, food-reinforced behavior and food aversions. Physiol Behav 2007;91:383-8.
75. Osei-Hyiaman D. Endocannabinoid system in cancer cachexia. Curr Opin Clin Nutr Metab Care 2007;10:443-8.
76. Monteleone P, Matias I, Martiadis V, et al. Blood levels of the endocannabinoid anandamide are increased in anorexia nervosa and in binge-eating disorder, but not in bulimia nervosa. Neuropsychopharmacology 2005;30:1216-21.
77. Côté M, Matias I, Lemieux I, et al. Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. Int J Obes 2007;31:692-9.
78. Engeli S, Böhnke J, Feldpausch M, et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes 2005;54:2838-43.
79. Blüher M, Engeli S, Klöting N, et al. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes 2006;55:3053-60.
80. Siegfried Z, Kanyas K, Latzer Y, et al. Association study of cannabinoid receptor gene (CNR1) alleles and anorexia nervosa: differences between restricting and binging/purging subtypes. Am J Med Genet B Neuropsychiatr Genet 2004;125:126-30.
81. Gomez R, Navarro M, Ferrer B, et al. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci 2002;22:9612-7.
82. Petersen G, Sorensen C, Schmid PC, et al. Intestinal levels of anandamide and oleoylethanolamide in food-deprived rats are regulated through their precursors. Biochim Biophys Acta 2006;1761:143-50.
83. Rucker D, Padwal R, Li SK, et al. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007;335:1194-9.
84. Christensen R, Kristensen PK, Bartels EM, et al. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 2007;370:1706-13.
85. Van Gaal LF, Rissanen AM, Scheen AJ, et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005;365:1389-97.
86. Després JP, Golay A, Sjöström L; Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005;353:2121- 34.
87. Scheen AJ, Finer N, Hollander P, et al; RIO-Diabetes Study Group. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006;368:1660-72.
88. Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006;295:761-75.
89. Foltin RW, Fischman MW, Brady JV, et al. The regularity of smoked marijuana self-administration. Pharmacol Biochem Behav 1989;32:483-6.
90. Beal JE, Olson R, Laubenstein L, et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage 1995;10:89-97.
91. Strasser F, Luftner D, Possinger K, et al. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis-In-Cachexia-Study-Group. J Clin Oncol 2006;24:3394-400.
92. Darmani NA. Methods evaluating cannabinoid and endocannabinoid effects on gastrointestinal functions. Methods Mol Med 2006;123:169-89.
93. Onaivi ES. Neuropsychobiological evidence for the functional presence and expression of cannabinoid CB2 receptors in the brain. Neuropsychobiology 2006;54:231-46.
94. Onaivi ES, Ishiguro H, Gong JP, et al. Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann NY Acad Sci 2006;1074:514-36.
95. Rock EM, Limebeer CL, Mechoulam R, et al. The effect of cannabidiol and URB597 on conditioned gaping (a model of nausea) elicited by a lithium-paired context in the rat. Psychopharmacology 2008;196:389-95.
96. Cross-Mellor SK, Ossenkopp KP, Piomelli D, et al. Effects of the FAAH inhibitor, URB597, and anandamide on lithium-induced taste reactivity responses: a measure of nausea in the rat. Psychopharmacology (Berl) 2007;190:135-43.
97. Sharma R, Tobin P, Clarke SJ. Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea. Lancet Oncol 2005;6:93-102.
98. Tramer MR, Carroll D, Campbell FA, et al. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 2001;323:16-21.
99. Allen JH, de Moore GM, Heddle R, et al. Cannabinoid hyperemesis: cyclical hyperemesis in association with chronic cannabis abuse. Gut 2004;53:1566-70.
100. Wallace D, Martin AL, Park B. Cannabinoid hyperemesis: marijuana puts patients in hot water. Australas Psychiatry 2007;15:156-8.
101. Esfandyari T, Camilleri M, Busciglio I, et al. Effects of a cannabinoid receptor agonist on colonic motor and sensory functions in humans: a randomized, placebo-controlled study. Am J Physiol Gastrointest Liver Physiol 2007;293:G137-45.
102. McCallum RW, Soykan I, Sridhar KR, et al. Delta-9-tetrahydrocannabinol delays the gastric emptying of solid food in humans: a double-blind, randomized study. Aliment Pharmacol Ther 1999;13:77-80.
103. Camilleri M, Carlson P, McKinzie S, et al. Genetic variation in endocannabinoid metabolism, gastrointestinal motility and sensation. Am J Physiol Gastrointest Liver Physiol 2008;294:G13-9.
104. Guagnini F, Cogliati P, Mukenge S, et al. Tolerance to cannabinoid response on the myenteric plexus of guinea-pig ileum and human small intestinal strips. Br J Pharmacol 2006;148:1165-73.
105. Izzo AA, Mascolo N, Borrelli F, et al. Excitatory transmission to the circular muscle of the guinea-pig ileum: evidence for the involvement of cannabinoid CB1 receptors. Br J Pharmacol 1998;124:1363-8.
106. Heinemann A, Shahbazian A, Holzer P. Cannabinoid inhibition of guinea-pig intestinal peristalsis via inhibition of excitatory and activation of inhibitory neural pathways. Neuropharmacology 1999;38:1289-97.
107. Mulè F, Amato A, Baldassano S, et al. Evidence for a modulatory role of cannabinoids on the excitatory NANC neurotransmission in mouse colon. Pharmacol Res 2007;56:132-9.
108. Izzo AA, Capasso R, Pinto L, et al. Effect of vanilloid drugs on gastrointestinal transit in mice. Br J Pharmacol 2001;132:1411-16.
109. Yuece B, Sibaev A, Broedl UC, et al. Cannabinoid type 1 receptor modulates intestinal propulsion by an attenuation of intestinal motor responses within the myenteric part of the peristaltic reflex. Neurogastroenterol Motil 2007;19:744-53.
110. Mathison R, Ho W, Pittman QJ, et al. Effects of cannabinoid receptor-2 activation on accelerated gastrointestinal transit in lipopolysaccharide-treated rats. Br J Pharmacol 2004;142:1247-54.
111. Sibaev A, Massa F, Yuce B, et al. CB1 and TRPV1 receptors mediate protective effects on colonic electrophysiological properties in mice. J Mol Med 2006;84:513-20.
112. Esfandyari T, Camilleri M, Ferber I, et al. Effect of a cannabinoid agonist on gastrointestinal transit and postprandial satiation in healthy human subjects: a randomized, placebo-controlled study. Neurogastroenterol Motil 2006;18:831-8.
113. 1 receptor-mediated in rats. Eur J Pharmacol 2000;409:207-11.
114. Green BT, Calvin A, O'Grady SM, et al. Kinin-induced anion-dependent secretion in porcine ileum: characterization and involvement of opioid- and cannabinoid-sensitive enteric neural circuits. J Pharmacol Exp Ther 2003;305:733-9.
115. Izzo AA, Mascolo N, Pinto L, et al. The role of cannabinoid receptors in intestinal motility, defaecation and diarrhoea in rats. Eur J Pharmacol 1999;384:37-42.
116. Vigna SR. Cannabinoids and the gut. Gastroenterology 2003;125:973-5.
117. Hillsley K, McCaul C, Aerssens J, et al. Activation of the cannabinoids 2 (CB2) receptor inhibits murine mesenteric afferent nerve activity. Neurogastroenterol Motil 19:769-77.
118. Blackshaw LA, Brookes SJ, Grundy D, et al. Sensory transmission in the gastrointestinal tract. Neurogastroenterol Motil 2007;19(1 Suppl):1-19.
119. Rousseaux C, Thuru X, Gelot A, et al. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med 2007;13:35-7.
120. Michalski CW, Laukert T, Sauliunaite D, et al. Cannabinoids ameliorate pain and reduce disease pathology in cerulein-induced acute pancreatitis. Gastroenterology 2007;132:1968-78.
121. Camilleri M. Is there a role for probiotics in irritable bowel syndrome? Dig Liver Dis 2006;38(Suppl 2):S266-9.
122. Ihenetu K, Molleman A, Parsons ME, et al. Inhibition of interleukin-8 release in the human colonic epithelial cell line HT-29 by cannabinoids. Eur J Pharmacol 2003;458:207-15.
123. Schwabe RF, Siegmund SV. Potential role of CB2 receptors in Cannabis smokers with chronic hepatitis C. Hepatology 2005;42:975-6.
124. Biecker E, Sägesser H, Reichen J. Vasodilator mRNA levels are increased in the livers of portal hypertensive NO-synthase 3-deficient mice. Eur J Clin Invest 2004;34:283-9.
125. Munoz-Luque J, Ros J, Femandez-Varo G, et al. Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in the cirrhotic rats. J Pharmacol Exp Ther 2008;324:475-83.
126. Domenicali M, Ros J, Fernandez-Varo G, et al. Increased anandamide induced relaxation in mesenteric arteries of cirrhotic rats: role of cannabinoid and vanilloid receptors. Gut 2005;54:522-7.
127. Ros J, Clària J, To-Figueras J, et al. Endogenous cannabinoids: a new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat. Gastroenterology 2002;122:85- 93.
128. Moezi L, Gaskari SA, Liu H, et al. Anandamide mediates hyperdynamic circulation in cirrhotic rats via CB(1) and VR(1) receptors. Br J Pharmacol 2006;149:898-908.
129. Yang YY, Lin HC, Huang YT, et al. Roles of anandamide in the hepatic microcirculation in cirrhotic rats. Am J Physiol Gastrointest Liver Physiol 2006;290:G328-34.
130. Mendez-Sanchez N, Zamora-Valdes D, Pichardo-Bahena R, et al. Endocannabinoid receptor CB2 in nonalcoholic fatty liver disease. Liver Int 2007;27:215-9.
131. 1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat Med 2006;12:671-6.
132. Fernández-Rodriguez CM, Romero J, Petras TJ, et al. Circulating endogenous cannabinoid anandamide and portal, systemic and renal hemodynamics in cirrhosis. Liver Int 2004;24:477-83.
133. Julien B, Grenard P, Teixeira-Clerc F, et al. Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology 2005;128:742-55.
134. Xu X, Liu Y, Huang S, et al. Overexpression of cannabinoid receptors CB1 and CB2 correlates with improved prognosis of patients with hepatocellular carcinoma. Cancer Genet Cytogenet 2006;171:31-8.
135. Batkai S, Osei-Hyiaman D, Pan H, et al. Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury. FASEB J 2007;21:1788-800.
136. Siegmund SV, Qian T, de Minicis S, et al. The endocannabinoid 2-arachidonoyl glycerol induces death of hepatic stellate cells via mitochondrial reactive oxygen species. FASEB J 2007;21:2798- 806.
137. Bátkai S, Járai Z, Wagner JA, et al. Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat Med 2001;7:827-32.
138. Biswas KK, Sarker KP, Abeyama K, et al. Membrane cholesterol but not putative receptors mediates anandamide-induced hepatocyte apoptosis. Hepatology 2003;38:1167-77.
139. Siegmund SV, Seki E. Osawa Y, et al. Fatty acid amide hydrolase determines anandamide-induced cell death in the liver. J Biol Chem 2006;281:10431-8.
140. Siegmund SV, Schwabe RF. Endocannabinoids in the pathogenesis and treatment of liver fibrosis. Am J Physiol Gastrointest Liver Physiol 2008;G357-62.
141. Mallat A, Teixeira-Clerc F, Deveaux V, et al. Cannabinoid receptors as new targets of antifibrosing strategies during chronic liver diseases. Expert Opin Ther Targets 2007;11:403-9.
142. Lotersztajn S, Teixeira-Clerc F, Julien B, et al. CB2 receptors as new therapeutic targets for liver diseases. Br J Pharmacol 2008;153:286-9.
143. Gabbay E, Avraham Y, Ilan Y, et al. Endocannabinoids and liver disease - review. Liver Int 2005;25:921-6.
144. Zamora-Valdés D, Ponciano-Rodríguez G, Chávez-Tapia NC, et al. The endocannabinoid system in chronic liver disease. Ann Hepatol 2005;4:248-54.
145. Siegmund SV, Uchinami H, Osawa Y, et al. Anandamide induces necrosis in primary hepatic stellate cells. Hepatology 2005;41:1085-95.
146. Giuliano M, Calvaruso G, Pellerito O, et al. Anandamide-induced apoptosis in Chang liver cells involves ceramide and JNK/AP-1 pathway. Int J Mol Med 2006;17:811-9.
147. Borini P, Guimarães RC, Borini SB. Possible hepatotoxicity of chronic marijuana usage. Sao Paulo Med J 2004;122:110-6.
148. Hézode C, Roudot-Thoraval F, Nguyen S, et al. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. Hepatology 2005;42:63-71.
149. Ishida JH, Peters MG, Jin C, et al. Influence of cannabis use on severity of hepatitis C disease. Clin Gastroenterol Hepatol 2008;6:69-75.
150. 2+-dependent potassium channels in in vitro anandamide-mediated mesenteric vasorelaxation in rats with biliary cirrhosis. Liver Int 2007;27:1045-55.
151. Yang YY, Lin HC, Huang YT, et al. Roles of anandamide in the hepatic microcirculation in cirrhotic rats. Am J Physiol Gastrointest Liver Physiol 2006;290:G328-34.
152. Gaskari SA, Liu H, Moezi L, et al. Role of endocannabinoids in the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats. Br J Pharmacol 2005;146:315-23.
153. Bátkai S, Mukhopadhyay P, Harvey-White J, et al. Endocannabinoids acting at CB1 receptors mediate the cardiac contractile dysfunction in vivo in cirrhotic rats. Am J Physiol Heart Circ Physiol 2007;293:H1689-95.
154. Avraham Y, Israeli E, Gabbay E, et al. Endocannabinoids affect neurological and cognitive function in thioacetamide-induced hepatic encephalopathy in mice. Neurobiol Dis 2006;21:237-45.
155. Dagon Y, Avraham Y, Ilan Y, et al. Cannabinoids ameliorate cerebral dysfunction following liver failure via AMP-activated protein kinase. FASEB J 2007;21:2431-41.
156. Kurabayashi M, Takeyoshi I, Yoshinari D, et al. 2-Arachidonoylglycerol increases in ischemia-reperfusion injury of the rat liver. J Invest Surg 2005;18:25-31.
157. Pacher P, Haskó G. Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning. Br J Pharmacol 2008;153:252-62.
158. Rajesh M, Pan H, Mukhopadhyay P, et al. Pivotal advance: cannabinoid-2 receptor agonist HU-308 protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis. J Leukoc Biol 2007;82:1382-9.
159. Osei-Hyiaman D, DePetrillo M, Pacher P, et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 2005;115:1298-305.
160. Gary-Bono M, Elachouri G, Gallas JF, et al. Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Hepatology 2007;46:122-9.
161. Serrano A, Del Arco I, Javier Pavón F, et al. The cannabinoid CB1 receptor antagonist SR141716A (Rimonabant) enhances the metabolic benefits of long-term treatment with oleoylethanolamide in Zucker rats. Neuropharmacology 2008;54:226-34.
162. Hézode C, Zafrani ES, Roudot-Thoraval F, et al. Daily cannabis use: a novel risk factor of steatosis severity in patients with chronic hepatitis C. Gastroenterology 2008;134:432-9.
163. Neff GW, O'Brien CB, Reddy KR, et al. Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease. Am J Gastroenterol 2002;97:2117-9.
164. Gingold AR, Bergasa NV. The cannabinoid agonist WIN 55, 212-2 increases nociception threshold in cholestatic rats: implications for the treatment of the pruritus of cholestasis. Life Sci 2003;73:2741-7.
165. Strazzabosco M, Fabris L, Spirli C. Pathophysiology of cholangiopathies. J Clin Gastroenterol 2005;39(4 Suppl 2):S90-102.
166. Bogert PT, LaRusso NF. Cholangiocyte biology. Curr Opin Gastroenterol 2007;23:299-305.
167. Alvaro D, Mancino MG, Glaser S, et al. Proliferating cholangiocytes: a neuroendocrine compartment in the diseased liver. Gastroenterology 2007;132:415-31.
168. Demorrow S, Francis H, Gaudio E, et al. Anandamide inhibits cholangiocyte hyperplastic proliferation via activation of thioredoxin 1/redox factor 1 and AP-1 activation. Am J Physiol Gastrointest Liver Physiol 2008;294:G506-19.
169. Matsuda K, Mikami Y, Takeda K, et al. The cannabinoid 1 receptor antagonist, AM251, prolongs the survival of rats with severe acute pancreatitis. Tohoku J Exp Med 2005;207:99-107.
170. Grant P, Gandhi P. A case of cannabis-induced pancreatitis. JOP 2004;5:41-43.
171. Wargo KA, Geveden BN, McConnell VJ. Cannabinoid-induced pancreatitis: a case series. JOP 2007;8:579-83.
172. Bifulco M, Laezza C, Pisanti S, et al. Cannabinoids and cancer: pros and cons of an antitumour strategy. Br J Pharmacol 2006, 148:123-35.
173. Fernández-Ruiz J, Romero J, Velasco G, et al. Cannabinoid CB2 receptor: a new target for controlling neural cell survival? Trends Pharmacol Sci 2007;28:39-45.
174. Greenhough A, Patsos HA, Williams AC, et al. The cannabinoid delta(9)-tetrahydrocannabinol inhibits RAS-MAPK and PI3K-AKT survival signalling and induces BAD-mediated apoptosis in colorectal cancer cells. Int J Cancer 2007;121:2172-80.
175. Joseph J, Niggemann B, Zaenker KS, et al. Anandamide is an endogenous inhibitor for the migration of tumor cells and T lymphocytes. Cancer Immunol Immunother 2004;53:723-28.
176. Notarnicola M, Messa C, Orlando A, et al. Estrogenic induction of cannabinoid CB1 receptor in human colon cancer cell lines. Scand J Gastroenterol 2007 [Epub ahead of print].
177. Patsos HA, Hicks DJ, Dobson RR, et al. The endogenous cannabinoid, anandamide, induces cell death in colorectal carcinoma cells: a possible role for cyclooxygenase 2. Gut 2005;54:1741-50.
178. Hashibe M, Straif K, Tashkin DP, et al. Epidemiologic review of marijuana use and cancer risk. Alcohol 2005;35:265-375.
179. Buckley NE. The peripheral cannabinoid receptor knockout mice: an update. Br J Pharmacol 2008;153:309-18.
180. DeMorrow S, Glaser S, Francis H, et al. Opposing actions of endocannabinoids on cholangiocarcinoma growth: recruitment of Fas and Fas ligand to lipid rafts. J Biol Chem 2007;282:13098-113.
181. Michalski CW, Oti FE, Erkan M, et al. Cannabinoids in pancreatic cancer: correlation with survival and pain. Int J Cancer 2008;122:742-50.
182. Carracedo A, Gironella M, Lorente M, et al. Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes. Cancer Res 2006;66:6748-55.
183. Hubbard JR, Franco SE, Onaivi ES. Marijuana: medical implications. Am Fam Physician 1999;60:2583-8.
184. Campbell FA, Tramèr MR, Carroll D, et al. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ 2001;323:13-6.
185. Huestis MA. Pharmacokinetics and metabolism of the plant cannabinoids, delta9-tetrahydrocannabinol, cannabidiol and cannabinol. Handb Exp Pharmacol 2005;168:657-90.
186. McPartland JM, Glass M, Pertwee RG. Meta-analysis of cannabinoid
187. Bisogno T, Hanus L, De Petrocellis L, et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 2001;134:845-52.
188. Cunha JM, Carlini EA, Pereira AE, et al. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 1980;21:175-85.
189. Consroe P, Laguna J, Allender J, et al. Controlled clinical trial of cannabidiol in Huntington's disease. Pharmacol Biochem Behav 1991;40:701-8.
190. Mechoulam R, Peters M, Murillo-Rodriguez E, et al. Cannabidiol - recent advances. Chem Biodivers 2007;4:1678-92.
191. Parker LA, Mechoulam R, Schlievert C. Cannabidiol, a non-psychoactive component of cannabis and its synthetic dimethylheptyl homolog suppress nausea in an experimental model with rats. Neuroreport 2002;13:567-70.
192. Parker LA, Mechoulam R. Cannabinoid agonists and antagonists modulate lithium-induced conditioned gaping in rats. Integr Physiol Behav Sci 2003;38:133-45.
193. Parker LA, Kwiatkowska M, Burton P, et al. Effect of cannabinoids on lithium-induced vomiting in the Suncus murinus (house musk shrew). Psychopharmacology 2004;171:156-61.
194. Ligresti A, Moriello AS, Starowicz K, et al. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J Pharmacol Exp Ther 318:1375-87.
195. Shook JE, Burks TF. Psychoactive cannabinoids reduce gastrointestinal propulsion and motility in rodents. J Pharmacol Exp Ther 1989;249:444-9.
196. Fride E, Ponde D, Breuer A, et al. Peripheral, but not central effects of cannabidiol derivatives: mediation by CB(1) and unidentified receptors. Neuropharmacology 2005;48:1117-9.
197. Capasso R, Bomelli F, Aviello G, et al. Cannabidiol, extracted from Cannabis sativa, selectively inhibits inflammatory hypermotility in mice. Br J Pharmacol 2008. [Epub ahead of print].